AI Article Synopsis
- Colon cancer is a common disease where cell growth and movement contribute to its severity, with INHBA identified as an important oncogene linked to poor patient outcomes.
- Research utilized TCGA datasets and various database analyses to explore INHBA's expression and its relationship with another factor, BHLHE40, in colon cancer cells.
- Findings indicate that silencing INHBA reduces colon cancer cell growth and migration, revealing that BHLHE40 regulates INHBA, thereby impacting cancer progression.
Article Abstract
Background: Colon cancer is highly prevalent, and cell proliferation and migration are major reasons for its progression to malignancy. The upregulation of INHBA, a glycoprotein hormone that regulates the secretion of pituitary hormones, is documented to be oncogenic in numerous cancers, consisting of breast, gastric, and ovarian cancer. Herein, we assessed the role of INHBA in the proliferation along with the migration of colon cancer cells.
Methods: TCGA datasets were used to assess INHBA expression and its correlation with prognosis in colon cancer patients. Analyses on JASPAR, PROMO, and ENCODE databases, uncovered high correlation between INHBA and BHLHE40. Western blot and RT-qPCR analysis were used to determine protein and mRNA levels. Cell transfection inhibited the expression of INHBA and BHLHE40. Cell proliferation rates were determined using CCK8 analysis. Wound healing assays were adopted to explore cell migration.
Results: INHBA is markedly elevated in colon cancer tissues along with cells and is a predictive factor for patient's prognosis with colon cancer. INHBA silencing suppressed colon cancer cell proliferation and migration. Furthermore, we confirmed the association of INHBA with BHLHE40 in colon cancer cells. BHLHE40 could directly modulates INHBA expression. Here, we show that BHLHE40 modulates the expression of INHBA, which influences the proliferation, and migration of colon cancer cells.
Conclusion: INHBA acts as an oncogene in colon cancer and it can be regulated by the transcription factor BHLHE40.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9279979 | PMC |
| http://dx.doi.org/10.1002/jcla.24539 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Patient-derived Organoids and Xenografts Uncover Therapeutic Vulnerabilities in Colorectal Signet Ring Cell Carcinomas.
Clin Cancer Res
January 2025
ACTREC, Tata Memorial Centre, Navi Mumbai, Maharashtra, India.
Purpose: Identifying therapeutic targets for Signet Ring Cell Carcinoma (SRCC) of the colon and rectum is a clinical challenge due to the lack of Patient-Derived Organoids (PDO) or Xenografts (PDX). We present a robust method to establish PDO and PDX models to answer address this unmet need. We demonstrate that these models identify novel therapeutic strategies targeting therapy resistance and peritoneal metastasis.
View Article and Find Full Text PDFGlobal prevalence and moderating factors of malnutrition in colorectal cancer survivors: A meta-analysis.
J Cancer Surviv
January 2025
School of Nursing, College of Nursing, Taipei Medical University, Taipei, Taiwan.
Purpose: This meta-analysis aims to estimate the global prevalence of severe, moderate, overall malnutrition and moderating factors of malnutrition in colorectal cancer (CRC) survivors.
Methods: A comprehensive search was conducted in Embase, CINAHL, Medline-OVID, PubMed, Scopus, and Web of Science from inception to February 8, 2024, without language, region, or publication date restrictions. A generalized linear mixed model and random-effects model were used to examine the pooled prevalence, and moderator analyses were implemented to investigate variations in the pooled prevalence.
Developing a novel model for predicting overall survival in late-onset colon adenocarcinoma patients based on LODDS: a study based on the SEER database and external validation.
Discov Oncol
January 2025
Department of General Surgery, The First Affiliated Hospital of Anhui Medical University, Hefei, 230000, China.
Aim: To construct a predictive model based on the LODDS stage established for patients with late-onset colon adenocarcinoma to enhance survival stratification.
Methods: Late-onset colon adenocarcinoma data were obtained from the public database. After determining the optimal LODDS truncation value for the training set via X-tile software, we created a new staging system by integrating the T stage and M stage.
Peranal Endoscopic Myectomy for Salvage Resection of a Neuroendocrine Tumor in the Lower Rectum.
Am J Gastroenterol
January 2025
Division of Endoscopy, Shizuoka Cancer Center, Shizuoka, Japan.
Decoding the RELARC trial - is D2 dissection sufficient in right colon cancer?
ANZ J Surg
January 2025
Colorectal Unit, Department of General Surgery, The Alfred, Melbourne, Victoria, Australia.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!